Report type: Weekly Strategy
Renewed Awareness of Climate Change Risks
During the week of 7/10, the Japanese stock market changed from that of the previous week, during which US economic indicators deteriorated one after another, to perform solidly with expectations for an agreement during the US-China ministerial-level meetings on 10-11/10. As a result of reports on the morning of 10/10 that the negotiations had broken down and that the Chinese delegation would be returning to China earlier than scheduled, the Nikkei Average dropped temporarily to 21,308 points. However, it bounced back to 21,700 points on 11/10 when the meeting between President Trump and Vice Premier Liu He proceeded as scheduled. However, with the exception of 11/10, which was the October futures/options SQ day, the market had been dull with slow transactions and with the TSE Section 1 trading value being less than two trillion yen.
Yaskawa Electric (6506) announced its 1H (Mar-Aug) results of FY 2020/2 on 10/10, and revised its full-year earnings forecast downward. The company’s business results serve as an important indicator of the condition of the Japanese stock market, as it is a leading indicator of other capital investment-related stocks, most of which usually announce financial results for the fiscal year ended March. President Ogasawara said that “postponements of semiconductor-related investments had been more severe than expected”. At the same time, he also gave positive indications, mentioning that “customer inventory adjustments are ending, and we do not expect further deteriorations”, reflecting the fact that orders received in China are bottoming out. In the semiconductor industry, the market for EUV (Extreme Ultra Violet) lithography, which is an indication of miniaturization processing needs, is rapidly rising, and such developments are good for the Japanese stock market.
The United Nations Climate Change Summit held on 23/9 once again strongly appealed to the world about the crisis involving climate change. Typhoon Faxai (Typhoon 15) had caused large-scale blackouts in Chiba Prefecture. As of 11/10, large and violent Typhoon Hagibis (Typhoon 19) is approaching the Japanese archipelago. Typhoons approaching Japan with scales largely exceeding the country’s assumed standards have become common. In this regard, there is an urgency to deal with ageing transmission lines and steel towers. Companies like Ito Yogyo (5287) are therefore becoming enthusiastic about the concept of “removing utility poles”. In addition to the headwinds facing coal-fired power plants globally, the restart of nuclear power plants, which are positioned as “important baseload power sources”, is difficult owing to political issues. In Japan, focus on renewable energy such as solar and wind power generation is expected to intensify. Furthermore, the flu season, which usually begins in early December, has already begun in October, perhaps due to large temperature differences as a result of the unstable climate. Please take care of your health.
In the 15/10 issue, we will be covering Komeda Holdings (3543), Sawai Pharmaceutical (4555), Weathernews (4825), Shiseido (4911), Canon (7751) and Aeon Mall (8905).
・Founded in 1968. Developing coffee house franchise business through brands such as “Komeda Coffee Shop”, “Okage-an” and “Yawaraka Shiro Koppe”. Company’s strengths are its ability to induce more frequent visits by nearby residents, capturing lower land rentals and leases by locating in suburban areas, structuring lean menus through shared use of ingredients, and capturing stable profits through low operating costs.
・For 1H (Mar-Aug) results of FY2020/2 announced on 9/10, revenue increased by 3.2% to 15.328 billion yen compared to the previous period, operating income increased by 6.4% to 3.932 billion yen, and net income increased by 6.0% to 2.651 billion yen. Applying IFRS 16, revenue decreased by 1.029 billion yen, but excluding this, revenue rose 10.1% to 16.357 billion yen. Introduction of seasonal products had contributed to results.
・For its full year plan, revenue is expected to increase by 1.0% to 30.638 billion yen compared to the previous year, operating income to increase by 4.0% to 7.869 billion yen, and current income to increase by 3.8% to 5.313 billion yen. According to Bloomberg, in addition to conducting surveys together with Mitsubishi Corp (8058) with regards opening a store in Thailand, company also seems to be training human resources in Myanmar with a view for them to work in Japan.
・Established in 1948. A leading manufacturer of generic drugs. Manufactures and sells non-prescription drugs and about 700 types of ethical drugs such as therapeutic agents for lifestyle-related illness (hypertension, dyslipidemia, diabetes etc) and anti-cancer drugs etc.
・For 1Q (Apr-Jun) results of FY2020/3 announced on 6/8, revenue increased by 4.1% to 47.134 billion yen compared to the same period the previous year, and core operating profit, excluding profit and loss due to non-recurring factors, increased by 18.7% to 10.646 billion yen. While sales and profits in the US had declined due to a decline in generic drug prices, those for Japan had increased due to strong sales in hospitals and pharmacies.
・For its full year plan, revenue is expected to remain at 184.4 billion yen compared to the previous year, core operating profit to decrease by 15.2% to 32.0 billion yen, and current income to decrease by 0.9% to 19.2 billion yen. Company is expected to face serious challenges, such as drug price revision in Japan due to the consumption tax increase, and the oligopoly of wholesalers and pharmacies in the US as well as the increase in the number of “Abbreviated New Drug Applications (ANDA)”. With the flu season in Japan beginning two months earlier than usual, outlook for the company, which deals with generic drugs for Tamiflu, looks good.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
